Norway: GE Healthcare increases API capacity

GE Healthcare’s Pharmaceutical Diagnostics business is investing US$80m to increase manufacturing capacity by 30 percent at its Active Pharmaceutical Ingredients (API) site in Lindesnes, Norway. The investment is part of GE Healthcare’s broader commitment to address future global demand for iodinated contrast media, used in Xray and Computed Tomography (CT) procedures to enhance visualization of…

You must be a HMI Subscriber to view this content.

Subscribe Now »